~~AMENDMENT UNDER ARTICLE 34~~

~~Replacement Sheets~~

CLAIMS

1. ~~A method of treating a viral infection caused by Lassa virus, corona virus including SARs-CoV-2, Zika virus, dengue virus, and Ebola virus, comprising the administration, to a patient in need thereof,~~ Use of a therapeutically effective amount of a compound of Formula II



(II)

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a viral infection caused by Lassa virus, corona virus including SARs-CoV-2, Zika virus, dengue virus, and Ebola virus, in a patient in need thereof,

wherein:

R_{14}, R_{15}, R_{16}, and R_{17} are independently selected from the group consisting of hydrogen, $COCH_3$, $COCH_2CH_3$, and $COCH_2CH_2CH_3$; and

R_4 and R_5 are independently selected from the group consisting of hydrogen, Cl, Br, I, ^{18}F, and ^{19}F, with the proviso that when R_4 and R_5 are both H, then at least one of R_{14} -R_{17} is not H.

2. The ~~method~~ use of claim 1, wherein R_4 and R_5 are independently selected from the group consisting of hydrogen, and I.

3. The ~~method~~ use of claim 1, wherein R_{14}, R_{15}, R_{16}, and R_{17} are independently selected from the group consisting of hydrogen and $COCH_3$.

4. ~~A method of treating a viral infection comprising the administration, to a patient in need thereof,~~ Use of a therapeutically effective amount of a compound selected from the group consisting of , ((2R,3S,4R)-4-acetoxy-3,6-dihydroxytetrahydro-2H-pyran-2-

yl)methyl acetate, (2-Deoxy-2-iodo-D-glucose), and (2-Deoxy-2-iodo-D-mannose), and pharmaceutically acceptable salts thereof, in the manufacture of a medicament, for treating a viral infection in a patient in need thereof.

5. The ~~method~~ use of claim 1, wherein said compound has the structural formula:



and pharmaceutically acceptable salts thereof.

6. The ~~method~~ use according to any one of claims 1-5, wherein said viral infection is caused by a corona virus including SARs-CoV-2.

7. The ~~method~~ use according to any one of claims 1-5, wherein said viral infection is caused by a virus characterized by glycosylated envelope proteins on infected cells.

8. The ~~method~~ use according to any one of claims 1-5, wherein the patient has COVID-19.

9. The ~~method~~ use according to any one of claims 1-5, wherein the patient tests positive for COVID-19.

10. The ~~method~~ use according to any one of claims 1-~~5~~9, wherein the patient is asymptomatic.

11. A pharmaceutical composition for the treatment of a viral infection comprising a pharmaceutically acceptable carrier together with a compound of structural Formula II



(II)

or a pharmaceutically acceptable salt thereof, wherein:

R_{14}, R_{15}, R_{16}, and R_{17} are independently selected from the group consisting of hydrogen, $COCH_3$, $COCH_2CH_3$, and $COCH_2CH_2CH_3$; and

R_4 and R_5 are independently selected from the group consisting of hydrogen, Cl, Br, I, ^{18}F, and ^{19}F, with the proviso that when R_4 and R_5 are both H, then at least one of R_{14} -R_{17} is not H.

12. The pharmaceutical composition of claim 11, wherein R_4 and R_5 are independently selected from the group consisting of hydrogen, and I.

13. The pharmaceutical composition of claim 12, wherein R_{14}, R_{15}, R_{16}, and R_{17} are independently selected from the group consisting of hydrogen and $COCH_3$.

14. A pharmaceutical composition for the treatment of a viral infection comprising a pharmaceutically acceptable carrier together with a compound selected from the group consisting of ((2R,3S,4R)-4-acetoxy-3,6-dihydroxytetrahydro-2H-pyran-2-yl)methyl acetate, (2-Deoxy-2-iodo-D-glucose), and (2-Deoxy-2-iodo-D-mannose), and pharmaceutically acceptable salts thereof.

15. The pharmaceutical composition of claim 11 wherein the compound is



or pharmaceutically acceptable salt thereof.

~~16. A compound for use in the manufacture of a medicament for the prevention or treatment of a viral infection caused by Lassa virus, corona virus including SARs-~~

CoV-2, Zika virus, dengue virus, and Ebola virus, said compound of structural Formula II



(II)

or a pharmaceutically acceptable salt thereof, wherein:

R_{14}, R_{15}, R_{16}, and R_{17} are independently selected from the group consisting of hydrogen, $COCH_3$, $COCH_2CH_3$, and $COCH_2CH_2CH_3$; and

R_4 and R_5 are independently selected from the group consisting of hydrogen, Cl, Br, I, ^{18}F, and ^{19}F, with the proviso that when R_4 and R_5 are both H, then at least one of R_{14}–R_{17} is not H.

17. The compound of claim 16, wherein R_4 and R_5 are independently selected from the group consisting of hydrogen, and I.

18. The compound of claim 17, wherein R_{14}, R_{15}, R_{16}, and R_{17} are independently selected from the group consisting of hydrogen and $COCH_3$.

19. A compound for use in the manufacture of a medicament for the prevention or treatment of a viral infection caused by Lassa virus, corona virus including SARs-CoV-2, Zika virus, dengue virus, and Ebola virus, wherein the compound is selected from the group consisting of ((2R,3S,4R)-4-acetoxy-3,6-dihydroxytetrahydro-2H-pyran-2-yl)methyl acetate, (2-Deoxy-2-iodo-D-glucose), and (2-Deoxy-2-iodo-D-mannose), and pharmaceutically acceptable salts thereof.

~~20. The compound for use in the manufacture of a medicament for the prevention or treatment of a viral infection according to claim 16, wherein said compound has the structural formula:~~



~~or a pharmaceutically acceptable salt thereof.~~

~~21~~16. The ~~method~~ use of any one of claims 1-~~5~~10, wherein the compound is to be administered by inhalation or insulfation.

17. The pharmaceutical composition of any one of claims 11-15, wherein said viral infection is caused by Lassa virus, corona virus including SARs-CoV-2, Zika virus, dengue virus, or Ebola virus.

18. The pharmaceutical composition of any one of claims 11-15, wherein said viral infection is caused by a corona virus including SARs-CoV-2.

19. The pharmaceutical composition of any one of claims 11-15, wherein said viral infection is caused by a virus characterized by glycosylated envelope proteins on infected cells.

20. The pharmaceutical composition of any one of claims 11-15, wherein the patient has COVID-19.

21. The pharmaceutical composition of any one of claims 11-15, wherein the patient tests positive for COVID-19.

22. The pharmaceutical composition of any one of claims 11-15, and 17-21, wherein the patient is asymptomatic.

23. The pharmaceutical composition of any one of claims 11-15, and 17-22, wherein said composition is suitable for administration by inhalation or insulfation.